[ad_1]
Shares of Tocagen Inc.
TOCA, -77.74%
Volumes fell 82% to a record high, which motivated Thursday all promoters of precursor drugs to commercialization, after the gene company said that an advanced-phase trial of its cancer treatment brain did not achieve its primary survival goal, compared to standard treatment. The trading volume of 975,000 shares prior to the opening of the market was already more than triple the average daily average of about 253,000 shares. The company stated that all of the secondary endpoints of the Phase 3 trial evaluating Toca 511 and Toca FC in patients with high-grade recurrent glioma being resected showed no significant difference between arm of the test. The company said that a more in-depth analysis of the test data was underway. The title is about to open below the $ 1 mark, below the previous record of nearly $ 3.00. It had already fallen 49.1% until Wednesday, while the S & P 500 [: spx] had gained 19.7%.
[ad_2]
Source link